Lannett Shares Update

• Announces Positive Results from Pivotal Clinical Insulin Trial that Demonstrates Biosimilarity to Reference Product
• Productive Conversations with Key Secured Creditors Toward a Balance Sheet Strengthening, Recapitalization or Restructuring Transaction Ongoing As Company Enters Grace Period for Failure

Ximluci, a Lucentis Biosimilar, Launches in Europe

Partners STADA Arzneimittel and Xbrane Biopharma have launched Ximluci, a ranibizumab biosimilar, in several European countries for the treatment of several ophthalmic conditions. Partners STADA Arzneimittel and Xbrane Biopharma have launched Ximluci, a

Bioanalytical Assays to support Denosumab 

Somru developed the following comprehensive list of  bioanalytical assays to support Denosumab biosimilar  development 

1. Pharmacokinetic Assay (PK) assay 
2. ADA assay 

• Binding ADA assay 
• Cell-based NAb assay(s) 
• Ligand Binding NAb Assay  

3. Pharmacodynamic Assays 

• sCTX 
• TRAP-5b 
• P1NP